Regeneron Pharmaceuticals Q3 2026 Earnings Conference Call - REGENERON PHARMACEUTICALS INC

Explicit Guidance:

• 2027 R&D Expense: Expected to increase by mid-teens percentage compared to 2026.
• 2027 Effective Tax Rate: Expected to face 100–200 basis points of upward pressure relative to 2026.
• 2026 Full-Year Share Repurchases: Expected to total approximately $3 billion (with $2.2 billion remaining in authorization as of September 30, 2026).
• Sanofi Collaboration Revenue: Expect to record the full $1 billion upfront payment in Q4 2026; future milestone payments recognized in full upon achievement.
• Inmazeb (Batraviren) Revenue: Do not anticipate recording any Inmazeb revenue in Q4 2026 due to a new barter agreement starting late 2027 through 2031; additional doses to be supplied to the U.S. government during this period.

Business-Segment Outlook:

• Dupixent (Sanofi Collaboration): Global net sales grew 35% YoY in Q3 2026 to $6.5 billion; U.S. net sales grew 40% to >$5 billion. The franchise is well-positioned for continued growth across all nine indications and new-to-brand prescriptions.
• Ilea-HD: Q3 2026 U.S. net sales reached an all-time high of ~$700 million. For Q4 2026, sequential physician unit demand is expected to grow ~10% (offset by pricing pressure), resulting in full-year 2026 net sales growth of >50% vs. 2025.
• Ilea (U.S.): Q3 2026 U.S. net sales were $400 million. For Q4 2026, sequential demand is expected to decline in the low-to-mid-teens.
• Pre-filled Syringe (Ilea-HD): Awaiting FDA approval; expected to drive further adoption if approved by year-end and sustain momentum in 2027 and beyond.
• Libtia: Q3 2026 U.S. net sales grew 81% to ~$400 million. An SBLA for a six-week dosing regimen (15-minute infusion) is under review with the FDA, with a decision expected by March 2027.
• Linazifix: Currently growing modestly in late-line; pivotal readouts expected for confirmatory trials in 2027 and first-line trials in 2028.
• Rare Diseases: FKESA growing 28% YoY in Q3 2026. Otarmony and Pasireum (for FOP) launched with promising initial progress.
• New Launches: Preparing for potential launch of Simdisiran in November pending FDA PDUFA for generalized myasthenia gravis.

Market and Competitive Outlook:

• MASH (Metabolic Dysfunction-Associated Steatohepatitis): The Side B program targets a genetically validated pathway, aiming to capture a market currently underserved by indirect approaches. Initial data suggests ~70% liver fat reduction, positioning it as a potential best-in-disease therapy.
• POTS (Postural Orthostatic Tachycardia Syndrome): No FDA-approved therapies currently exist; the company anticipates its antibody could be the first approved treatment for a condition affecting 500,000 to several million U.S. patients.
• Ovarian Cancer: Ubematumab shows ~70% objective response rate in low-grade serous ovarian cancer, significantly outperforming historical chemotherapy (<15%) and current approved biologic therapies (44% in biomarker-selected patients).
• Type 2 Inflammation: Next-generation alliance candidates aim to address unmet needs for less frequent dosing compared to Dupixent while maintaining efficacy/safety.
• Obesity (Oloreotide): Differentiation strategy involves co-formulation with Praluent (PCSK9 antibody) to target comorbid obesity, diabetes, and hypercholesterolemia, aiming to reduce lipid/cardiometabolic risk alongside weight loss.
• Competition: Management notes that competitor "heavily engineered" long-acting antibodies may face higher risks of anti-drug antibodies compared to Regeneron's natural, fully human systems.

Macro / Industry Outlook:

• Pipeline Progress: Expect to initiate >15 Phase 3 trials this year alone.
• Regulatory Milestones:
  • Simdisiran: FDA decision expected November 2026.
  • Ogenexamab: FDA decision on relapsed/refractory diffuse large B-cell lymphoma application expected February 2027.
  • C5-SRNA (Systemic): European Commission decision anticipated in H2 2027.
  • C5-SRNA (GA): Interim 26-week data expected in early 2027.
  • Ubematumab: Confirmatory Phase 3 trial planned to start in mid-2027.
  • Linazifix: Pivotal readouts in 2027 (1L/2L) and 2028 (1L transplant-ineligible).
  • Oloreotide: Registrational studies of combination therapy expected to begin next year.
  • Food Allergy: Clinical studies of new bispecific (targeting IgE plasma cells) planned for first half of 2027.
• Geographic Expansion: Expansion of alliance with Sanofi leverages global commercialization; Regeneron to lead R&D for next-gen long-acting antibodies.
• Capacity/Manufacturing: No specific new capacity additions mentioned, but focus on co-formulation and systemic administration approaches (e.g., C5-SRNA) to treat bilateral disease.

Strategic Initiatives:

• Sanofi Alliance Expansion: Advancing four next-generation, long-acting, fully human VelocImmune-derived antibodies and bispecifics targeting IL-4/IL-13 pathways. Lead IL-13 antibody (dosing interval 3–6 months) enrollment ongoing; registration trials expected late 2027–2028. Three additional candidates (IL-4/13 bispecific, IL-4R alpha antibody, IL-4 ligand antibody) expected to enter clinic next year.
• POTS Study: Planning to initiate a potentially registrational study in H1 2027 pending regulatory feedback.
• Ovarian Cancer: Enrolling a potentially registrational cohort for ubematumab; confirmatory Phase 3 trial planned for mid-2027.
• Anticoagulation: Sengisibar and Mresibar Phase 3 studies are mostly enrolled; pivotal results for knee replacement program expected next year; secondary stroke prevention study enrollment expected by year-end.
• MASH: Advancing Side B into registration-enabling studies; first-in-human data presentation scheduled for November liver meeting.
• Business Development: Open to opportunities at all stages (early to commercial) with a focus on strategic fit and valuation; currently prioritizing internal pipeline over external acquisitions unless superior.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Approval of Simdisiran (Nov 2026), Ogenexamab (Feb 2027), and Ilea-HD pre-filled syringe remain contingent on FDA decisions.
• Clinical Readout Timing: Specific timelines for pivotal results (e.g., C5-SRNA GA data in 2027, Oloreotide trials next year) are subject to enrollment rates and regulatory feedback.
• Competitive Pressure: Biosimilar launches (Flibercept 2mg) impacting Ilea net sales growth; competitors developing their own long-acting antibodies.
• Revenue Timing: No Inmazeb revenue expected in Q4 2026 due to barter agreement structure.
• Pricing Pressure: Ongoing pricing pressure noted as a factor partially offsetting volume growth for Ilea-HD in Q4 2026.
• Development Risks: Success of MASH and POTS programs depends on replicating early clinical data in larger trials; safety profiles of new bispecifics remain to be fully established.

Management Tone on the Future:

• Confidence: High confidence in the "broad and diverse pipeline" and "business-agnostic enterprise approach." Management describes the current quarter as "exceptional" and the future as "bright."
• Differentiation Focus: Strong emphasis on "first-in-class" or "best-in-disease" potential driven by human genetics validation (e.g., Side B, Simdisiran).
• Strategic Shift: Moving from a net outlicenser to a more balanced approach, leveraging financial strength for differentiated external innovation while maintaining focus on internal R&D productivity.
• Commercial Execution: Expresses strong confidence in the commercial organization's ability to launch across new specialties (neurology) and existing franchises despite competition.

Miscellaneous:

• Alliance Economics: Under the amended Sanofi agreement, R&D costs and global profits for the four next-generation antibodies will be shared 50-50; existing terms for Dupixent and Kevzara remain unchanged.
• Q3 2026 Financials: Total revenue grew 36% to $5.1B; diluted net income per share grew 70% to $20.07.
• Cash Position: Generated $2.9B free cash flow through the first nine months of 2026; ended quarter with $16.2B in cash and marketable securities (net of debt).
• Tax Rate: Q3 2026 effective tax rate was 15%, driven by a shift in geographic income mix favoring higher-taxed Sanofi collaboration revenue.